What is TRVI (TRVI) stock price today?

TRVI (TRVI) is currently trading at $18.51, up 0.05% today.

What is TRVI P/E ratio?

TRVI's P/E ratio is -28.11. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is TRVI return on equity (ROE)?

TRVI's return on equity (ROE) is -33.59%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is TRVI's market cap?

TRVI has a market capitalization of $2.63B.

NASDAQ · Biotechnology

TRVI (TRVI) Stock

$18.51 +0.05% NASDAQ: TRVI Healthcare

Valuation

Metric	Value
Price	$18.51
Market Cap	$2.63B
P/E Ratio	-28.11
P/B Ratio	10.34
P/S Ratio	0.00
EPS (TTM)	$-0.32
52-Week High	$19.79
52-Week Low	$5.38
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-33.59%
ROA	-23.01%
ROCE	-26.78%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	24.75

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-32.0M	$-30.0M	$-34.0M	$-52.0M	$-49.0M
Net Profit	$-34.0M	$-29.0M	$-29.0M	$-48.0M	$-43.0M
EPS	$-1.49	$-0.45	$-0.29	$-0.47	$-0.29
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$38.0M	$123.0M	$89.0M	$111.0M	$193.0M
Total Liabilities	$21.0M	$16.0M	$7.0M	$11.0M	$10.0M
Cash	$37.0M	$13.0M	$32.0M	$34.0M	$19.0M
Borrowings	$15.0M	$9.0M	$1.0M	$1.0M	$1.0M

Latest News

BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target MT Newswires · Jul 21, 2026 B. Riley Adjusts Trevi Therapeutics Price Target to $31 From $21, Maintains Buy Rating MT Newswires · Jul 20, 2026 Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market Insider Monkey · Jul 18, 2026 Trevi Therapeutics Announces Upcoming June and July Event Schedule GlobeNewswire · Jun 17, 2026 Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. Motley Fool · Jun 3, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-29.0M	$-28.0M	$-32.0M	$-38.0M	$-42.0M
Investing Cash Flow	$0	$-108.0M	$59.0M	$-22.0M	$-94.0M
Financing Cash Flow	$0	$12.0M	$0	$0	$1.0M
Net Cash Flow	$-8.0M	$-24.0M	$20.0M	$2.0M	$-15.0M
Free Cash Flow	$-29.0M	$-28.0M	$-32.0M	$-38.0M	$-42.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-261.45
EV / EBITDA	-36.57
FCF Yield	-1.52%
Quick Ratio	24.75
Interest Coverage	—
Return 1Y	148.00%
Return 3Y	638.72%
Return 5Y	776.77%

Ownership

Insiders Held0.63%

Institutions Held99.26%

Institutions Float Held99.89%

Institutional Holder	Shares	Report Date
NEA Management Company, LLC	13,222,228	2026-03-31
Blackrock Inc.	10,240,186	2026-03-31
Frazier Life Sciences Management, L.P.	9,939,547	2026-03-31
FMR, LLC	8,038,061	2026-03-31
Wellington Management Group, LLP	5,189,088	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ARDX	$5.09	+0.49%	11.04	$1.26B	0.00%
NVAXNovavax, Inc.	$7.61	+2.01%	-13.81	$1.25B	0.00%
ORIC	$13.50	+4.41%	-5.39	$1.40B	0.00%
PGEN	$5.45	-1.45%	-2.99	$1.94B	0.00%
TERNTerns Pharmaceuticals, Inc.	$52.95	-0.04%	-51.41	$4.77B	0.00%

About TRVI

TRVI stock trades at $18.51 with a market capitalization of $2.63B. The stock is valued at a price-to-earnings (P/E) ratio of -28.11, price-to-book of 10.34, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.38 and $19.79, and currently trades 6.5% below its 52-week high.

On profitability, TRVI generates a return on equity (ROE) of -33.59%, return on capital employed of -26.78%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides